According to the research report titled ‘Global Generic Injectables Market (2022 Edition) - Analysis By Molecule Type, (Small, Large), Therapeutic Area, Container Type, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2022-2027)’, available with MarketStudyReport, global generic injectables market was worth USD 134 billion in 2021 and is anticipated to witness stellar growth through 2027.

Report findings suggest that expiration of branded medicine patents, rising approvals for generic injectable drugs, ever-increasing elderly population, and growing prevalence of life-threatening diseases among the worldwide population are some of the significant factors driving global generic injectables market expansion.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4814124/  

Furthermore, comparatively inexpensive cost of product as compared to the branded medicines that are used to treat critical ailments such as cardiovascular disease, cancer, diabetes, and other conditions, is expected to augment industry outlook in the coming years.

Notably, the COVID-19 outbreak caused restriction of movement such as social isolation, public gathering prohibitions, travel restrictions, border closures, and work from home mandates, due to worldwide lockdown measures to avoid the spread of the virus, which along with delayed clinical trials and prohibited laboratory visits hampered the market progress in the recent past.

Based on molecule type, the market is split into large molecule and small molecule. In terms of therapeutic area, worldwide generic injectables industry is branched into diabetes, cardiovascular, anti-infectives, oncology, and others. On the basis of container, the marketplace is divided into pre-filled syringes, ampoules, vials, and others.

Regionally speaking, North America industry holds major revenue share at present, with the United States at the forefront. Whereas Asia Pacific market is slated to expand considerably during the forecast period, owing to shifting focus of Indian firms towards complicated generics and the rising usage of generic injectables due to their cost-effective nature, along with growing prevalence of chronic diseases.

Nichi-Iko Pharmaceutical Co., Ltd., Gland Pharma Limited, Hikma Pharmaceuticals plc, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Sanofi S.A., Fresenius SE & Co. KGaA, Novartis International AG, and Pfizer Inc. are the leading players in global generic injectables industry.